A Phase 4 interventional study of Olanzapine and Aripiprazole in Schizophrenia, sponsored by Eli Lilly and Company. Completed at 5 sites in 2 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2007-11-06.
Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 97 studies testing olanzapine in Schizophrenia — 2 open to participants now, 3 under way, 1 of them phase 3. Olanzapine · Schizophrenia.
Among the 97 studies testing olanzapine in Schizophrenia, this one is the 9th largest by enrollment of the 94 interventional ones that give a count, is one of 10 that started in 2004, is one of 46 in phase 4, and was the 16th registered.
3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →2 of the 97 studies testing olanzapine in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:
Minerva Neurosciences · Sites in United States
Ages 18–55
Centre for Addiction and Mental Health · Sites in Canada
Ages 18+
By country, each count listing its studies:
Olanzapine: first FDA approval 1996 (ZYPREXA), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
97 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 8 · Phase 3 25 · Phase 4 46
First in 1997; this study’s year is marked. 10 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 600 is above the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 114 across the 94 interventional studies. Of the 86 that completed or were terminated, 25 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 97 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
33 studies in Schizophrenia by Eli Lilly and Company: 2 open now, 2 under way, none of them phase 3. Of 31 finished, 9 (29%) have results posted.
Among the 33 studies in Schizophrenia by Eli Lilly and Company, this one is the 4th largest by enrollment of the 29 interventional ones that give a count, is one of 7 that started in 2004, is one of 16 in phase 4, and was the 13th registered.
Eli Lilly and Company’s Schizophrenia studies by the year they started, since 2001.
2 of the studies testing olanzapine in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03781115University of ArizonaProposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia | 2027-02-10 |
| NCT04478838Centre for Addiction and Mental Health"Extended" (Alternate Day) Antipsychotic Dosing | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 97 studies testing olanzapine in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 33 in Schizophrenia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purposes of this study are to assess similarities and differences in the efficacy (how well the drug works), safety, and side effects of olanzapine and aripiprazole in patients with schizophrenia, schizoaffective disorder, or schizophreniform disorder.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The primary objective of this study is to test the hypothesis that olanzapine is superior to aripiprazole in the reduction of symptoms of agitation in acutely ill patients with schizophrenia, as measured by mean change in the
Positive and Negative Syndrome Scale Excited Component (PANSS-EC) over 5 days of treatment (4 continuous 24 hr treatment exposures). The null hypothesis of the study is that there is no difference between olanzapine and
aripiprazole in reducing agitation.
The reduction in positive symptoms as measured by the Brief Psychiatric Rating Scale Positive subscale (PBRS Positive);
The reduction of symptoms of agitation as measured by Overt Agitation Severity Scale (OASS);
The proportion of patients responding to treatment and the time to response based on varying levels in the percent reduction of
the PANSS_EC from baseline;
The reduction in overall severity of psychiatric illness as measured by the Clinical Global Impression-Severity Scale (CGI-S);
The intensity of nursing intervention (e.g. seclusion, restraint, special nursing watch), as measured by the Global Assessment
of Nursing Intervention
The proportion of patients using pm lorazepam and the time-course of usage.
The proportion of patients discontinuing from the study due to lack of efficacy or due to adverse events related to worsening
of psychiatric illness.
Patient satisfaction with their medication, as measured by Drug Attitude Inventory (DA1-10).
A sensitivity analysis will be performed on two randomly chosen subsamples of the overall patient population by analyzing the
primary objective respectively.
Additional secondary objectives of the study are to compare the safety of olanzapine versus aripiprazole over the course of 5
days in the treatment of acutely ill patients with schizophrenia as assessed by:
Relative degree of sedation as measured by the Agitation Calmness Evalution Scale (ACES);
Review of spontaneous (unsolicited) treatment emergent adverse events;
Development of extrapyramidal symptoms as assessed by daily Modified Simpson-Angus and Barnes Akathisia scale scores.
The record gives a start of Jul 2004 and a completion of Aug 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2007. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Olanzapine · Aripiprazole